Valuation: Immunic, Inc.

Market Cap 219M 189M 178M 162M 304M 20.96B 308M 2.08B 817M 10.48B 821M 803M 34.91B P/E 2026 *
-4.31x
P/E 2027 * -6.36x
Enterprise Value -61.18M -52.84M -49.72M -45.19M -84.99M -5.86B -86.23M -583M -229M -2.93B -230M -225M -9.77B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day+4.24%
1 week+6.98%
Current month+18.54%
1 month+10.40%
3 months+42.02%
6 months+88.80%
Current year+210.29%
1 week 15.15
Extreme 15.15
16.97
1 month 12.73
Extreme 12.7267
16.97
Current year 5.37
Extreme 5.372
16.97
1 year 5.06
Extreme 5.062
16.97
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 2026-05-31
Director of Finance/CFO 58 2020-04-16
President 49 2024-07-11
Director TitleAgeSince
Director/Board Member 59 2019-03-31
Chairman 55 2018-12-31
Director/Board Member 64 2019-11-18
Date Insider Type Main position Quantity % Market Cap.
8/6/26 Free

Director

50,740 0.3725%
7/5/26 Free

Director

25,370 0.1862%
7/5/26 Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
+4.46%+6.98%+69.24%+2.86% 219M
+0.17%+3.62%+70.94%+109.68% 73.25B
+1.73%+16.15%+51.73%+93.89% 61.95B
+0.14%-3.05%+0.99%+491.46% 28.02B
+5.24%+5.33%+57.01%+17.77% 24.15B
+0.82%-0.46%-17.93%-16.30% 23.01B
-0.71%+5.26%+241.94%+427.03% 18.35B
0.00%+5.57%+39.57%-14.30% 19.46B
+3.83%+2.65%+25.00%+592.85% 15.92B
+1.52%+3.57%+40.78%+151.94% 12.96B
Average +1.70%+2.48%+57.93%+185.69% 27.73B
Weighted average by Cap. +1.22%+3.44%+56.06%+168.20%

Financials

2026 *2027 *
Net sales - -
Net income -139M -120M -113M -103M -193M -13.32B -196M -1.32B -519M -6.66B -522M -510M -22.18B -151M -131M -123M -112M -210M -14.5B -213M -1.44B -565M -7.25B -568M -556M -24.16B
Net Debt -280M -242M -227M -207M -389M -26.82B -395M -2.67B -1.05B -13.41B -1.05B -1.03B -44.68B -404M -349M -328M -298M -561M -38.69B -569M -3.85B -1.51B -19.35B -1.52B -1.48B -64.45B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
26-08-18 US$16.57 +3.37% 86,285
26-08-17 US$16.03 -0.19% 160,400
26-08-14 US$16.06 -3.14% 79,672
26-08-13 US$16.58 +4.08% 165,590
26-08-12 US$15.93 +2.91% 299,382
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.03USD
Average target price
42.18USD
Spread / Average Target
+163.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock